Bristol Myers Squibb (BMY) Lobbying Data
BMY lobbying summary
Bristol Myers Squibb Company (BMY) has reported $62.3M in federal lobbying spending across 237 Senate LDA filings since 2020. Its most frequent lobbying issues are Medicare/Medicaid, Health Issues, Taxation, Trade. Lobbying firms used include Bristol-Myers Squibb Company, Splitoak Strategies LLC, Crossroads Strategies, LLC.
Lobbying spending by year
| Year | Reported spend |
|---|---|
| 2026 | $9.6M |
| 2025 | $11.2M |
| 2024 | $6.5M |
| 2023 | $10.1M |
| 2022 | $6.4M |
| 2021 | $7.3M |
See insider trading for BMY or the Lobbying Heavyweights strategy.
Source: Senate Lobbying Disclosure Act (LD-2) filings. The current year is partial.